ScripThe list of companies that have made money out of a gene therapy is extremely short but Ferring Pharmaceuticals has a case for inclusion given the sales growth last year of its bladder cancer treatmen
Pink SheetThe novel candidates under US Food and Drug Administration review in oncology and neuroscience, its two biggest pending therapy areas, highlight the deep inroads precision medicine has made in contemp
ScripCG Oncology believes that the Phase III data for its oncolytic immunotherapy for bladder cancer show that cretostimogene grenadenorepvec can spare patients bladder surgery, and analysts said the data
ScripJohnson & Johnson 's 2019 acquisition of privately held TARIS Biomedical LLC for an undisclosed sum is looking like a canny move after new data from early trials of its lead product, TAR-200, sugges